204 related articles for article (PubMed ID: 8611359)
1. Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients.
Furth S; Neu A; Colombani P; Plotnick L; Turner ME; Fivush B
Pediatr Nephrol; 1996 Feb; 10(1):64-6. PubMed ID: 8611359
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
3. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506).
Moxey-Mims MM; Kay C; Light JA; Kher KK
Transplantation; 1998 Mar; 65(5):617-9. PubMed ID: 9521193
[TBL] [Abstract][Full Text] [Related]
4. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.
Pirsch JD; Miller J; Deierhoi MH; Vincenti F; Filo RS
Transplantation; 1997 Apr; 63(7):977-83. PubMed ID: 9112351
[TBL] [Abstract][Full Text] [Related]
5. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single-center report.
Birk PE; Cook ME; Schmidt WJ; Chavers BM
Transplant Proc; 1996 Apr; 28(2):993-4. PubMed ID: 8623493
[No Abstract] [Full Text] [Related]
6. Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation.
Barone GW; Ketel BL; Abul-Ezz SR; Lightfoot ML
JOP; 2002 Mar; 3(2):49-53. PubMed ID: 11884766
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
Forsythe J
Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
[No Abstract] [Full Text] [Related]
8. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients.
McKee M; Segev D; Wise B; Case B; Neu A; Fivush B; Colombani P
J Pediatr Surg; 1997 May; 32(5):688-90. PubMed ID: 9165452
[TBL] [Abstract][Full Text] [Related]
9. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.
Wagner K; Webber SA; Kurland G; Boyle GJ; Miller SA; Cipriani L; Griffith BP; Fricker FJ
J Heart Lung Transplant; 1997 Mar; 16(3):275-82. PubMed ID: 9087870
[TBL] [Abstract][Full Text] [Related]
10. Pediatric renal transplantation under tacrolimus-based immunosuppression.
Shapiro R; Scantlebury VP; Jordan ML; Vivas C; Ellis D; Lombardozzi-Lane S; Gilboa N; Gritsch HA; Irish W; McCauley J; Fung JJ; Hakala TR; Simmons RL; Starzl TE
Transplantation; 1999 Jan; 67(2):299-303. PubMed ID: 10075598
[TBL] [Abstract][Full Text] [Related]
11. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506).
Moxey-Mims MM
Transplantation; 1999 Jul; 68(2):320. PubMed ID: 10440413
[No Abstract] [Full Text] [Related]
12. Diabetic ketoacidosis in a child on FK506 immunosuppression after a liver transplant.
Keshavarz R; Mousavi MA; Hassani C
Pediatr Emerg Care; 2002 Feb; 18(1):22-4. PubMed ID: 11862133
[TBL] [Abstract][Full Text] [Related]
13. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tacrolimus: clinically relevant aspects.
Undre NA; Stevenson P; Schäfer A
Transplant Proc; 1999 Nov; 31(7A):21S-24S. PubMed ID: 10576037
[No Abstract] [Full Text] [Related]
15. Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics.
Eghtesad B; Malhotra D; Hecker WP; Haq M; Gibel LJ; Wheeler D; Smith AY; Harford AM
Transplant Proc; 1998 Jun; 30(4):1232-3. PubMed ID: 9636500
[No Abstract] [Full Text] [Related]
16. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy?
Franz M; Regele H; Schmaldienst S; Stummvoll HK; Hörl WH; Pohanka E
Transplantation; 1998 Nov; 66(9):1258-62. PubMed ID: 9825827
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus in transplant rejection.
Rath T
Expert Opin Pharmacother; 2013 Jan; 14(1):115-22. PubMed ID: 23228138
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
Miller J; Mendez R; Pirsch JD; Jensik SC
Transplantation; 2000 Mar; 69(5):875-80. PubMed ID: 10755543
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of tacrolimus (FK506) with azathioprine and steroids in renal transplant recipients.
Yoshimura N; Oka T; Ohmori Y; Yasumura T; Nakai I; Hamashima T; Nakajima H; Okamoto M; Nakamura K; Mizuta N
Transplant Proc; 1998 Feb; 30(1):33-5. PubMed ID: 9474949
[No Abstract] [Full Text] [Related]
20. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.
Webster A; Woodroffe RC; Taylor RS; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003961. PubMed ID: 16235347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
